When it comes to auto-injectors for severe allergies, the EpiPen has been the go-to product for decades. But there are some clear inconveniences with the device designed to treat anaphylaxis, and some companies are trying to remedy this while still keeping the efficacy where it should be in such emergency situations.
Christopher J. Stepanian, co-founder and CEO of Windgap Medical, and his team are trying to do just that. He talked about a new device in the works at MedCity CONVERGE this week.
Hey, check out all the engineering jobs. Post your resume today!
